2018-04-24 14:52:07

Market Overview
According to a new report published by Reports Monitor titled, “Neurosyphilis Market by Type, Diagnosis, Treatment and End-User: Global Opportunity Analysis and Industry Forecast, 2017–2025,” the neurosyphilis market was valued at XX million in 2016, and is projected to reach at XX million by 2025, growing at a CAGR of XX% from 2017 to 2025. 

Lately prevalence of sexually transmitted disease has been growing. Neurosyphilis is the chronic disease of the covering of the brain, the brain itself and the spinal cord affecting the whole nervous system. The condition is caused by Treponema pallidum spirochete. Major risk factors for neurosyphilis are HIV and untreated syphilis. The medical condition comprises symptoms such as loss of vision & hearing ability, headache, stiff neck, nausea, vomiting, loss of reflexes & loss of sense, impaired balance and altered mental abilities. Asymptomatic neurosyphilis is the most common type of neurosyphilis.

Request a Sample Copy @

Huge spending by administrative bodies as well as private organization for research and development and routine involvement of population for clinical trials drives the neurosyphilis market.  Additionally, companies spending large amount of money to derive effective cure for neurosyphilis enforces the market growth. Moreover, advancement in technology, developing healthcare sectors, government supportive activities and awareness among populace is anticipated to evoke further market growth. However, lengthy approval procedure and rigid guidelines might act as obstacle hampering growth of the market. America is the potential market for neurosyphilis treatment. Availability of funding for clinical trials & research, highly developed healthcare infrastructure and progressive screening & diagnostic method strengthen the neurosyphilis market in the region.

The global neurosyphilis market is segmented on the basis of type, diagnosis, treatment, end-user and region. On the basis of type the market is categorized into asymptomatic, meningeal neurosyphilis, neurosyphilis, meningovascular neurosyphilis, general paresis, tabes dorsalis, and others. Based on diagnosis method market is separated into physical exam, blood test, imaging test, spinal tap and others. Depending upon treatment market is spilt into antibiotic probenecid, ceftriaxone, antibiotic penicillin and others. In terms of end-user the market is segmented into hospital & clinics, academic institutes, medical research centers and others. 

Competitive Scenario
Key players in the neurosyphilis market include: Abbott, GlaxoSmithKline plc., Sanofi, Eli Lilly and Company, Pfizer Inc., Bayer AG and Novartis AG

About Garner Insights:

We at Garner provide a comprehensive analysis by providing in-depth reports of the various market verticals. Our Mission is to provide a detailed analysis of the vast markets worldwide backed by rich data. Decision makers can now rely on our well-defined data gathering methods to get the correct and accurate market forecasting along with detailed analysis.

Contact Us:

Kevin Thomas


+1 513 549 5911 (US)

+44 203 318 2846 (UK)

Email: [email protected] 

Related Press Releases